Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study

被引:58
|
作者
Dassau, Eyal [1 ,2 ]
Renard, Eric [3 ,4 ,5 ]
Place, Jerome [5 ]
Farret, Anne [3 ,4 ,5 ]
Pelletier, Marie-Jose [3 ,4 ]
Lee, Justin [2 ]
Huyett, Lauren M. [2 ]
Chakrabarty, Ankush [1 ]
Doyle, Francis J., III [1 ,2 ]
Zisser, Howard C. [2 ]
机构
[1] Harvard Univ, Harvard John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA
[2] Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA
[3] Univ Hosp Montpellier, Dept Endocrinol Diabet Nutr, Montpellier, France
[4] Univ Hosp Montpellier, INSERM, Clin Invest Ctr 1411, Montpellier, France
[5] Univ Montpellier, CNRS UMR5203, Inst Funct Genom, INSERM U1191,Dept Psychol, Montpellier, France
来源
DIABETES OBESITY & METABOLISM | 2017年 / 19卷 / 12期
基金
美国国家卫生研究院;
关键词
artificial pancreas; CGM; closed-loop; CSII; DiaPort; hyperglycaemia; hypoglycaemia intraperitoneal; insulin pump; model predictive control; type; 1; diabetes; SEVERE HYPOGLYCEMIA; PUMP THERAPY; INFUSION; MELLITUS; GLUCOSE; SYSTEM; REDUCTION; CROSSOVER; OPTION;
D O I
10.1111/dom.12999
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To compare intraperitoneal (IP) to subcutaneous (SC) insulin delivery in an artificial pancreas (AP). Research design and methods: Ten adults with type 1 diabetes participated in a non-randomized, non-blinded sequential AP study using the same SC glucose sensing and Zone Model Predictive Control (ZMPC) algorithm adjusted for insulin clearance. On first admission, subjects underwent closed-loop control with SC delivery of a fast-acting insulin analogue for 24 hours. Following implantation of a DiaPort IP insulin delivery system, the identical 24-hour trial was performed with IP regular insulin delivery. The clinical protocol included 3 unannounced meals with 70, 40 and 70 g carbohydrate, respectively. Primary endpoint was time spent with blood glucose (BG) in the range of 80 to 140 mg/dL (4.4-7.7 mmol/L). Results: Percent of time spent within the 80 to 140 mg/dL range was significantly higher for IP delivery than for SC delivery: 39.8 7.6 vs 25.6 +/- 13.1 (P = .03). Mean BG (mg/dL) and percent of time spent within the broader 70 to 180 mg/dL range were also significantly better for IP insulin: 151.0 +/- 11.0 vs 190.0 +/- 31.0 (P = .004) and 65.7 +/- 9.2 vs 43.9 +/- 14.7 (P = .001), respectively. Superiority of glucose control with IP insulin came from the reduced time spent in hyperglycaemia (>180 mg/dL: 32.4 +/- 8.9 vs 53.5 +/- 17.4, P = .014; >250 mg/dL: 5.9 +/- 5.6 vs 23.0 +/- 11.3, P = .0004). Higher daily doses of insulin (IU) were delivered with the IP route (43.7 +/- 0.1 vs 32.3 +/- 0.1, P < .001) with no increased percent time spent <70 mg/dL (IP: 2.5 +/- 2.9 vs SC: 4.1 +/- 5.3, P = .42). Conclusions: Glycaemic regulation with fully-automated AP delivering IP insulin was superior to that with SC insulin delivery. This pilot study provides proof-of-concept for an AP system combining a ZMPC algorithm with IP insulin delivery.
引用
收藏
页码:1698 / 1705
页数:8
相关论文
共 41 条
  • [21] Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial
    Haidar, Ahmad
    Yale, Jean-Francois
    Lovblom, Leif Erik
    Cardinez, Nancy
    Orszag, Andrej
    Falappa, C. Marcelo
    Gouchie-Provencher, Nikita
    Tsoukas, Michael A.
    El Fathi, Anas
    Rene, Jennifer
    Eldelekli, Devrim
    Lanctot, Sebastien O.
    Scarr, Daniel
    Perkins, Bruce A.
    DIABETES OBESITY & METABOLISM, 2021, 23 (06): : 1272 - 1281
  • [22] Effects of subcutaneous vs. oral nanoparticle-mediated insulin delivery on hemostasis disorders in type 1 diabetes: A rat model study
    Kaddour, Nawel
    Benyettou, Farah
    Moulai, Kawtar
    Mebarki, Abdelouahab
    Allal-Taouli, Katia
    Ghemrawi, Rose
    Whelan, Jamie
    Merzouk, Hafida
    Trabolsi, Ali
    Mokhtari-Soulimane, Nassima Amel
    HELIYON, 2024, 10 (09)
  • [23] Comparison of Control-IQ and open-source AndroidAPS automated insulin delivery systems in adults with type 1 diabetes: The CODIAC study
    Do, Quoc Dat
    Haskova, Aneta
    Radovnicka, Lucie
    Konecna, Judita
    Horova, Eva
    Parkin, Christopher G.
    Grunberger, George
    Prazny, Martin
    Soupal, Jan
    DIABETES OBESITY & METABOLISM, 2024, 26 (01): : 78 - 84
  • [24] COMPARISON OF GLYCAEMIC CONTROL WHEN TRANSITIONING TO AN HYBRID CLOSED-LOOP INSULIN DELIVERY SYSTEM IN PEOPLE WITH TYPE 1 DIABETES: A SINGLE CENTRE OBSERVATIONAL STUDY
    Corcillo, A.
    Le Dizes, O.
    Wojtusciszyn, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A3 - A3
  • [25] Insulin infusion rate control using information theoretic-based nonlinear model predictive control for type 1 diabetes patients
    Birjandi, Sahar Zadeh
    Sani, Seyed Kamal Hosseini
    Pariz, Naser
    TRANSACTIONS OF THE INSTITUTE OF MEASUREMENT AND CONTROL, 2023, 45 (05) : 815 - 827
  • [26] A Randomized Crossover Pilot Study Evaluating Glucose Control During Exercise Initiated 1 or 2 h After a Meal in Adults with Type 1 Diabetes Treated with an Automated Insulin Delivery System
    Myette-Cote, Etienne
    Molveau, Josephine
    Wu, Zekai
    Raffray, Marie
    Devaux, Marie
    Tagougui, Semah
    Rabasa-Lhoret, Remi
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 (02) : 122 - 130
  • [27] Robust regulation of blood glucose for Type-1 diabetes using insulin infusion limiter-based feedback control via artificial Pancreas
    Manzoor, Sajida
    Rehan, Muhammad
    Ahmed, Ijaz
    MATHEMATICS AND COMPUTERS IN SIMULATION, 2025, 235 : 1 - 15
  • [28] An insulin infusion advisory system for type 1 diabetes patients based on non-linear model predictive control methods
    Zarkogianni, Konstantia
    Mougiakakou, Stavroula G.
    Prountzou, Aikaterini
    Vazeou, Andriani
    Bartsocas, Christos S.
    Nikita, Konstantina S.
    2007 ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-16, 2007, : 5972 - +
  • [29] Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial
    Haidar, Ahmad
    Legault, Laurent
    Messier, Virginie
    Mitre, Tina Maria
    Leroux, Catherine
    Rabasa-Lhoret, Remi
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (01): : 17 - 26
  • [30] Report of a 7 year case-control study of continuous intraperitoneal insulin infusion and subcutaneous insulin therapy among patients with poorly controlled type 1 diabetes mellitus: Favourable effects on hypoglycaemic episodes
    van Dijk, P. R.
    Logtenberg, S. J. J.
    Groenier, K. H.
    Gans, R. O. B.
    Bilo, H. J. G.
    Kleefstra, N.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 (02) : 256 - 263